[(177)Lu]Lu-PSMA-617 (Pluvicto(TM)): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer

In March 2022, [(177)Lu]Lu-PSMA-617 (Pluvicto(TM)) was approved by the FDA for the treatment of prostate cancer patients. Until now, the approval has been limited to patients with PSMA-positive metastatic castration-resistant prostate cancer who have previously received other therapy options (such a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hennrich, Ute, Eder, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608311/
https://www.ncbi.nlm.nih.gov/pubmed/36297404
http://dx.doi.org/10.3390/ph15101292
Descripción
Sumario:In March 2022, [(177)Lu]Lu-PSMA-617 (Pluvicto(TM)) was approved by the FDA for the treatment of prostate cancer patients. Until now, the approval has been limited to patients with PSMA-positive metastatic castration-resistant prostate cancer who have previously received other therapy options (such as inhibition of the androgen receptor pathway and taxane-based chemotherapy). [(177)Lu]Lu-PSMA-617, which combines a PSMA-specific peptidomimetic with a therapeutical radionuclide, is used in a radioligand therapy that selectively delivers ionizing radiation to tumor cells, causing their death, while sparing the surrounding healthy tissue. In numerous clinical trials, the efficacy of [(177)Lu]Lu-PSMA-617 was demonstrated.

Ejemplares similares